Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles

被引:11
作者
Oder, Daniel [1 ,2 ,3 ]
Vergho, Dorothee [1 ,2 ,3 ]
Ertl, Georg [1 ,2 ,3 ]
Wanner, Christoph [1 ,2 ,3 ]
Nordbeck, Peter [1 ,2 ,3 ]
机构
[1] Univ Hosp Wurzburg, Dept Internal Med 1, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany
[2] Univ Hosp Wurzburg, CHFC, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany
[3] Univ Hosp Wurzburg, Fabry Ctr Interdisciplinary Therapy FAZIT, Wurzburg, Germany
关键词
Fabry disease; Cryptogenic stroke; Pain; Hypertrophic cardiomyopathy; Chronic kidney disease; ENZYME REPLACEMENT THERAPY; X-INACTIVATION; CLINICAL MANIFESTATIONS; CARDIOMYOPATHY; VARIANT; RECOMMENDATIONS; POPULATION; DIAGNOSIS; COHORT; IMPACT;
D O I
10.1186/s12881-016-0309-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: X-chromosomal inheritance patterns and generally rare occurrence of Fabry disease (FD) account for mono-mutational hemizygous male and heterozygous female patients. Female mutation carriers are usually clinically much less severely affected, which has been explained by a suggested mosaicism in cell phenotype due to random allele shutdown. However, clinical evidence is scarce and potential additional effects in female gene carriers, which might account for specific clinical characteristics such as less severe chronic kidney disease, are yet unknown. Case presentation: This article reports on a 45 year old female patient carrying the two alpha-galactosidase A gene mutations c.416A>G, p.N139S in exon 3 and c.708G>C, p.W236C in exon 5, but still showing only mild organ manifestations. Conclusion: This current case highlights the importance of careful clinical characterization in patients with Fabry disease, who may show additional rare constellations and, therefore, are in need of personalized medicine. The impact of potential additional protective effects exceeding the presence of a non-pathogenic GLA allele in female gene carriers requires further investigation.
引用
收藏
页数:6
相关论文
共 21 条
[1]  
Davies JP, 1996, EUR J HUM GENET, V4, P219
[2]   Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy [J].
Desnick, RJ ;
Brady, R ;
Barranger, J ;
Collins, AJ ;
Germain, DP ;
Goldman, M ;
Grabowski, G ;
Packman, S ;
Wilcox, WR .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (04) :338-346
[3]   Relationship between X-inactivation and clinical involvement in Fabry heterozygotes.: Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population [J].
Dobrovolny, R ;
Dvorakova, L ;
Ledvinova, J ;
Magage, S ;
Bultas, J ;
Lubanda, JC ;
Elleder, M ;
Karetova, D ;
Pavlikova, M ;
Hrebicek, M .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2005, 83 (08) :647-654
[4]   X-inactivation in Fabry disease [J].
Elstein, Deborah ;
Schachamorov, Ella ;
Beeri, Rachel ;
Altarescu, Gheona .
GENE, 2012, 505 (02) :266-268
[5]   The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies [J].
Ferreira, Susana ;
Ortiz, Alberto ;
Germain, Dominique P. ;
Viana-Baptista, Miguel ;
Caldeira-Gomes, Antonio ;
Camprecios, Marta ;
Fenollar-Cortes, Maria ;
Gallegos-Villalobos, Angel ;
Garcia, Diego ;
Antonio Garcia-Robles, Jose ;
Egido, Jesus ;
Gutierrez-Rivas, Eduardo ;
Antonio Herrero, Jose ;
Mas, Sebastian ;
Oancea, Raluca ;
Peres, Paloma ;
Manuel Salazar-Martin, Luis ;
Solera-Garcia, Jesus ;
Alves, Helena ;
Garman, Scott C. ;
Oliveira, Joao Paulo .
MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) :248-258
[6]   Fabry disease:: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasma [J].
Froissart, R ;
Guffon, N ;
Vanier, MT ;
Desnick, RJ ;
Maire, I .
MOLECULAR GENETICS AND METABOLISM, 2003, 80 (03) :307-314
[7]   Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease [J].
Germain, Dominique P. ;
Charrow, Joel ;
Desnick, Robert J. ;
Guffon, Nathalie ;
Kempf, Judy ;
Lachmann, Robin H. ;
Lemay, Roberta ;
Linthorst, Gabor E. ;
Packman, Seymour ;
Scott, C. Ronald ;
Waldek, Stephen ;
Warnock, David G. ;
Weinreb, Neal J. ;
Wilcox, William R. .
JOURNAL OF MEDICAL GENETICS, 2015, 52 (05) :353-358
[8]   Fabry disease [J].
Germain, Dominique P. .
ORPHANET JOURNAL OF RARE DISEASES, 2010, 5
[9]   Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women [J].
Havndrup, Ole ;
Christiansen, Michael ;
Stoevring, Birgitte ;
Jensen, Morten ;
Hoffman-Bang, Jakob ;
Andersen, Paal Skytt ;
Hasholt, Lis ;
Norremolle, Anne ;
Feldt-Rasmussen, Ulla ;
Kober, Lars ;
Bundgaard, Henning .
EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (06) :535-540
[10]   Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease [J].
Kraemer, Johannes ;
Niemann, Markus ;
Liu, Dan ;
Hu, Kai ;
Machann, Wolfram ;
Beer, Meinrad ;
Wanner, Christoph ;
Ertl, Georg ;
Weidemann, Frank .
EUROPEAN HEART JOURNAL, 2013, 34 (21) :1587-1596